**Effectiveness of Care Measure** 

# Comprehensive Diabetes Care



Health Net<sup>\*</sup> and CalViva Health want to help your practice increase Healthcare Effectiveness Data and Information Set (HEDIS<sup>®</sup>) rates. This tip sheet outlines key details of the Comprehensive Diabetes Care (CDC) measure, its codes and guidance for documentation.

# Measure Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each of the following:1 Image: Patients ages 18–75 with diabetes (type 1 and type 2) who had each d

# Exclusions

- Patients without a diagnosis of diabetes but with a diagnosis of one of the following during the measurement year or year prior:
  - Gestational diabetes
  - Steroid-induced diabetes
- Patients who meet the following criteria anytime during the measurement year:
  - Patients in hospice

### HbA1c testing and control

An HbA1c test performed during the measurement year (MY) with value. Depending on the test value, patients will fall into different categories of control: • HbA1c control < 8.0%

• HbA1c poor control > 9.0%<sup>2</sup>

| Medical record documentation and best practices                                    | CPT/CPT II codes            |              |
|--|-----------------------------|--------------|
| • Need date and most recent result during measurement year in chart – use reported | HbA1c tests                 | 83036, 83037 |
| value and not threshold for result.  | HbA1c tests and level <7.0% | 3044F        |
| • HbA1c should be completed 2–4 times per year.                                    | HbA1c tests and level       | 3045F        |
| • The last HbA1c result of the year counts toward the HEDIS score.                 | 7.0-9.0%                    |              |
| Re-evaluate care plan and repeat testing as needed.                                | HbA1c tests and level >9.0% | 3046F        |

<sup>1</sup>NCQA. HEDIS 2019 Technical Specifications for Health Plans, Volume 2, Washington, D.C., 2018. <sup>2</sup>A lower rate indicates better performance for this indicator.

(continued)



| Blood pressure (BP) control (<140/90 mm Hg) <sup>3</sup>   |                               |       |  |
|--|-------------------------------|-------|--|
| The most recent BP reading taken during outpatient visit, non-acute inpatient encounter or remote monitoring event during the measurement year (MY). |                               |       |  |
| Medical record documentation and best practices  | CPT/CPT II codes              |       |  |
| • The last of reading of the year counts toward the reors score.   | Systolic <130 mm Hg           | 3074F |  |
|  | Systolic between 130–139mm Hg | 3075F |  |
|  | Systolic ≥140 mm Hg           | 3077F |  |
|  | Diastolic <80 mm Hg           | 3078F |  |
|  | Diastolic between 80–89 mm Hg | 3079F |  |
|  | Diastolic ≥90 mm Hg           | 3080F |  |
| - Consider medication adjustments and/or additions if BP is still out of control.  |                               |       |  |

<sup>3</sup>Please see Controlling Blood Pressure Tip Sheet for more recommendations and best practices.

| <sup>3</sup> Please see Controlling Blood Pressure Tip Sheet for more recommendations and best practices.   |  |   |  |
|---|--|---|--|
| Retinal eye exam  |  |   |  |
| <ul> <li>Eye screening or monitoring for diabetic retinal disease. This includes diabetics who had any</li> <li>A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist</li> <li>A retinal or dilated eye exam by an eye care professional in the year prior to the MY that w</li> <li>Bilateral eye enucleation anytime during patient's history through December 31 of the MY.</li> </ul>   | ) in the MY.<br>/as negative for retinopathy.  |   |  |
| Medical record documentation and best practices   | CPT/CPT II codes   |   |  |
| <ul> <li>Need date of service eye exam was rendered by an eye care professional and the results (specialty must be noted). or</li> <li>A chart or photograph indicating the date when fundus photography was performed with evidence that the eye care professional reviewed the results. Alternatively, results may be read by a qualified reading center that operates under the direction of a medical director who is a retinal specialist. or</li> <li>Evidence that member had bilateral eye enucleation: <ul> <li>Unilateral eye enucleation with a bilateral modifier</li> <li>Two unilateral eye enucleations with service dates 14 days or more apart</li> <li>Left unilateral eye enucleation and right unilateral enucleation on the same or different dates of service</li> </ul> </li> <li>Documentation of a negative retinal or dilated eye exam must clearly note that the retinopathy was not present in the medical record.</li> <li>Review eye exam report (from an eye care professional) and place it in patient's medical record.</li> </ul> | Dilated retinal eye exam<br>with interpretation by<br>an ophthalmologist or<br>optometrist and reviewed                        | 2022F   |  |
|   | 7 standard field stereoscopic<br>photos with interpretation by an<br>ophthalmologist or optometrist<br>documented and reviewed | 2024F   |  |
|   | Eye imaging validated to<br>match diagnosis from 7<br>standard field stereoscopic<br>photo results documented<br>and reviewed  | 2026F   |  |
|   | Low risk for retinopathy (no<br>evidence of retinopathy in the<br>prior year)  | 3072F   |  |
|   | Unilateral eye enucleation   | 65091, 65093, 65101, 65103,<br>65105, 65110, 65112, 65114 |  |
|   | Unilateral eye enucleation left  | 08B10ZX, 08B10ZZ, 08B13ZX,<br>08B13ZZ, 08B1XZX, 08B1XZZ   |  |
|   | Unilateral eye enucleation<br>right  | 08B00ZX, 08B00ZZ, 08B03ZX,<br>08B03ZZ, 08B0XZX, 08B0XZZ   |  |

(continued)

### Medical attention for nephropathy

A nephropathy screening or monitoring test or evidence of nephropathy. This includes diabetics who had any of the following:

- A nephropathy screening or monitoring test.
- Evidence of treatment for nephropathy or angiotensin converting enzyme (ACE) or angiotensin receptor blocker (ARB) therapy.
- Evidence of stage 4 chronic kidney disease (CKD), end-stage renal disease (ESRD), kidney transplant, or nephrology visit.
- At least one ACE inhibitor or ARB dispensing event.

| Medical record documentation and best practices   | CPT/CPT II codes   |   |
|---|--|---|
| <ul> <li>Date urine protein screening was completed with result, or</li> <li>Confirmatory documentation such as proteinuria (unspecific), albuminuria (specific), BUN/creatinine ratio (urine), or</li> <li>Documentation of a visit to a nephrologist or kidney transplant, or</li> <li>Documentation of medical attention for ESRD, chronic renal failure (CRF), CKD, acute renal failure (ARF), or renal insufficiency, or</li> <li>Clear evidence that patient received ACE/ARB therapy during the MY: <ul> <li>Documentation that a prescription for an ACE/ARB was written, or</li> <li>Documentation that patient took an ACE/ARB</li> </ul> </li> </ul> | Urine protein tests  | 81000–81003, 81005,<br>82042–82044, 84156 |
|   | Positive microalbuminuria<br>test result documented and<br>reviewed  | 3060F                                     |
|   | Negative microalbuminuria<br>test result documented and<br>reviewed  | 3061F                                     |
|   | Positive macroalbuminuria<br>test result documented and<br>reviewed  | 3062F                                     |
|   | Documentation of treatment<br>for nephropathy (includes<br>visit to nephrologist, patient<br>receiving dialysis, patient<br>being treated for ESRD, CRF,<br>ARF, or renal insufficiency) | 3066F                                     |
|   | ACE or ARB therapy prescribed or currently being taken   | 4010F                                     |

## Ace Inhibitor/ARB Medications

| Description                                    | Prescription   |  |  |  |
|--|--|--|--|--|
| Angiotensin<br>converting<br>enzyme inhibitors | <ul><li>Benazepril</li><li>Captopril</li></ul>   | <ul><li>Enalapril</li><li>Fosinopril</li></ul>   | <ul><li>Lisinopril</li><li>Moexipril</li></ul>   | <ul><li>Perindopril</li><li>Quinapril</li><li>Trandolapril</li></ul>   |
| Angiotensin II<br>inhibitors                   | • Azilsartan<br>• Candesartan  | • Eprosartan<br>• Irbesartan   | • Losartan<br>• Olmesartan   | • Telmisartan<br>• Valsartan   |
| Antihypertensive<br>combinations               | <ul> <li>Aliskiren-valsartan</li> <li>Amlodipine-benazepril</li> <li>Amlodipine-<br/>hydrochlorothiazide-<br/>valsartan</li> <li>Amlodipine-<br/>hydrochlorothiazide-<br/>olmesartan</li> <li>Amlodipine-olmesartan</li> <li>Amlodipine-perindopril</li> </ul> | <ul> <li>Amlodipine-telmisartan</li> <li>Amlodipine-valsartan</li> <li>Azilsartan-chlorthalidone</li> <li>Benazepril-<br/>hydrochlorothiazide</li> <li>Candesartan-<br/>hydrochlorothiazide</li> <li>Captopril-<br/>hydrochlorothiazide</li> </ul> | <ul> <li>Enalapril-<br/>hydrochlorothiazide</li> <li>Eprosartan-<br/>hydrochlorothiazide</li> <li>Fosinopril-<br/>hydrochlorothiazide</li> <li>Hydrochlorothiazide-<br/>irbesartan</li> <li>Hydrochlorothiazide-<br/>lisinopril</li> </ul> | <ul> <li>Hydrochlorothiazide-losartan</li> <li>Hydrochlorothiazide-moexipril</li> <li>Hydrochlorothiazide-olmesartan</li> <li>Hydrochlorothiazide-quinapril</li> <li>Hydrochlorothiazide-telmisartan</li> <li>Hydrochlorothiazide-valsartan</li> <li>Sacubitril-valsartan</li> <li>Trandolapril-verapamil</li> </ul> |

### 3 of 3

CalViva Health is a licensed health plan in California that provides services to Medi-Cal enrollees in Fresno, Kings and Madera counties. CalViva Health contracts with Health Net Community Solutions, Inc. to provide and arrange for network services. \*Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.